Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445804 · ClinicalTrials.gov registry record · Phase 1
Oral Cannabidiol for Tobacco Cessation
A Phase 1 study of Tobacco Use and Tobacco Use Disorder, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05445804: Recruiting Phase 1 study of Tobacco Use and Tobacco Use Disorder, sponsored by Johns Hopkins University.
NCT05445804 is a Phase 1 study of Tobacco Use and Tobacco Use Disorder that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 50 participants, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05445804, a Phase 1 study of Tobacco Use and Tobacco Use Disorder, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.
Primary Outcome
Biochemically-verified tobacco abstinence as assessed by expired carbon monoxide part per million during the 4-day practice quit attempt of each drug condition.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 300 mg Cannabidiol
- DRUG 600 mg Cannabidiol
Study Locations (1)
Maryland
- Johns Hopkins Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
What NCT05445804 shows while recruiting
NCT05445804 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (87% lower).
The record links to 5 conditions, with Tobacco Use appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05445804 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05445804 about?
NCT05445804 is a clinical study titled "Oral Cannabidiol for Tobacco Cessation". Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increa...
What is the current status of trial NCT05445804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-11-01. Estimated completion is 2027-02-01.
What conditions does trial NCT05445804 study?
This clinical trial studies the following conditions: Tobacco Use, Tobacco Use Disorder, Tobacco Smoking, Tobacco Use Cessation, Tobacco Dependence.
What interventions are being tested in trial NCT05445804?
The interventions under investigation include: Placebo (DRUG), 300 mg Cannabidiol (DRUG), 600 mg Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT05445804?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05445804 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05445804's enrollment target sits among peer trials
50 54th of 76 higher than 22 of 76 other Tobacco Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Effect of Cannabis on E-Cigarette Use Behavior
RECRUITING · Phase 1
-
Emergency Department Initiated Tobacco Treatment (EDITT)
COMPLETED · Phase 1
-
Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes
COMPLETED · Phase 1
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI